Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPX-304
- Development stage
- Preclinical
- Lead developer
- SPARX THERAPEUTICS
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SPX-304 is a preclinical bispecific monoclonal antibody developed by SparX Biotech. It is engineered to simultaneously target Programmed cell death 1 ligand 1 (PD-L1) and Leukocyte surface antigen CD47 (CD47). The dual-targeting mechanism is designed to enhance anti-tumor immunity by blocking the PD-1/PD-L1 checkpoint axis to restore T-cell activity while concurrently inhibiting the CD47/SIRPα "don't eat me" signaling pathway to promote macrophage-mediated phagocytosis of cancer cells. SPX-304 was identified through SparX's proprietary SAILING platform, which utilizes AI-driven optimization for the discovery of multi-specific antibodies. As of 2024, the program remains in the early discovery or preclinical stage, primarily intended for the treatment of solid tumors.
- Other names
- SPX304SPX-304SPX 304
02
Targets
CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on SPX-304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPX-304.